Adicet Bio, Inc. Finance Lease, Right-of-Use Asset, Amortization
Adicet Bio, Inc. (ACET) reported Finance Lease, Right-of-Use Asset, Amortization of $54.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-05
- Adicet Bio, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $54.00K.
- Adicet Bio, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $55.00K.
- Adicet Bio, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was -$17.00K.
- Adicet Bio, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $28.00K.
- Adicet Bio, Inc. finance lease, right-of-use asset, amortization for fiscal 2025 was $83.00K.
- Adicet Bio, Inc. finance lease, right-of-use asset, amortization for fiscal 2024 was $0.00.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $54.00K 10-Q · filed 2026-08-05 | $100.00K 10-Q · filed 2026-08-05 | $92.00K derived: sum of 3 quarters · filed 2026-08-05 | $120.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $55.00K 10-Q · filed 2026-05-13 | $38.00K derived: sum of 2 quarters · filed 2026-05-13 | $66.00K derived: sum of 3 quarters · filed 2026-05-13 | |
| 2025-12-31 | -$17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $11.00K derived: sum of 2 quarters · filed 2026-03-12 | $83.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | $28.00K 10-Q · filed 2025-11-05 | $100.00K 10-Q · filed 2025-11-05 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |